TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02049255
Drug: Marcaine
Normalized name: Marcaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The Group Marcaine will receive: Marcaine: 12,5 mg in rachianesthesia
Study: NCT03412474
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study drugs will be prepared by an anesthesiologist not involved in performing the block, patient care or in data collection. Patients will be randomly allocated into two groups of 40 patients each:~Group A: will receive 0.2 ml/kg/side of bupivacaine (0.125%).
Study: NCT03412474
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group B: will receive 0.2 ml/kg/side of bupivacaine (0.125%) + 0.5 µ/kg of dexmedetomidine.
Study: NCT03412474
Drug: paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: paracetamol
Study: NCT01477151
Drug: Volatile anesthetic
Normalized name: coal tar pitch volatiles
DrugBank: Coal tar (DB11082)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention in this trial is randomization to either maintenance of anesthesia with sevoflurane or maintenance of anesthesia with isoflurane. The designated volatile anesthetic will be given at a strict minimal amount throughout the entire cardiac surgery (including cardiopulmonary bypass). This regimen (administration throughout the entire operation) has proved to have the greatest efficacy. Apart from this intervention, the anesthetic for patients participating in this trial will not be substantially different from normal practice, as the intention is to allow normal practice (with the exception of the choice of volatile anesthetic agent) to maximize the applicability and external validity of the trial. The management of anticoagulation, cardiac surgical techniques, and other aspects of the procedure will be managed in an unaltered fashion.~No IV drug infusions will be permitted until after protamine administration.
Study: NCT02975440
Drug: Rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 11 single oral doses of 600 mg Rifampicin resulting in a total dose of 6600 mg Rifampicin.
Study: NCT02975440
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 single oral doses of 1 mg Midazolam resulting in a total dose of 2 mg Midazolam
Study: NCT02975440
Drug: BAY1002670_Vilaprisan
Normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 single oral doses of 4 mg Vilaprisan resulting in a total dose of 8 mg Vilaprisan
Study: NCT01012193
Drug: cilostazol 100mg bid or clopidogrel 150-mg daily
Normalized name: cilostazol 100 MG
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adjunctive cilostazol: cilostazol 100-mg bid +clopidogrel 75mg daily+aspirin 200mg daily High-MD clopidogrel: clopidogrel 150mg daly +aspirin 200mg daily
Study: NCT00494871
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants orally administered rivaroxaban 15 mg OD (CrCL \[creatinine clearance\] \>= 50 mL/min) or 10 mg OD (CrCL 30-49 mL/min)
Study: NCT00494871
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants orally administered a warfarin potassium tablet (INR \[international normalized ratio\] target was 1.6-2.6 for patients \>70 years and 2.0-3.0 for patients \<70 years)
Study: NCT00494871
Drug: Rivaroxaban placebo
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants orally administered a rivaroxaban placebo tablet
Study: NCT00494871
Drug: Warfarin placebo
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants orally administered a warfarin placebo tablet (adjusted based upon sham INR values)
Study: NCT01829802
Drug: Ritonavir boosted Atazanavir
Normalized name: atazanavir and ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir boosted Atazanavir 300/100 mg QD in combination with other drugs
Study: NCT01829802
Drug: Raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Raltegravir 400 BID in combination with Ritonavir boosted Atazanavir 300/100 mg QD during 48 weeks
Study: NCT00218855
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tablets thalidomide start 100 mg x 2 escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. The same procedure is repeated by first relapse.
Study: NCT01755195
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, metastasis, and angiogenesis, and targets primarily mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2).
Study: NCT01132677
Drug: Methylprednisolone (Corticosteroid)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single IA injection of 80mg of methylprednisolone acetate (1cc of solution) mixed with 5cc's of 1% lidocaine without epinephrine for a total of 6cc's. The injection will be administered as outlined on the company label.
Study: NCT02491437
Drug: Dydrogesterone 30 mg
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Dydrogesterone 10 mg tablets tid
Study: NCT02491437
Drug: intravaginal progesterone gel 90 mg
Normalized name: progesterone Vaginal Gel
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01790893
Drug: aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00029848
Drug: Rimonabant (SR141716)
Normalized name: rimonabant
DrugBank: Rimonabant (DB06155)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT01328249
Drug: eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose dense doxorubicin and cyclophosphamide for 4 cycles during the first 8 weeks followed by eribulin mesylate 1.4mg/m2 for 4 cycles during the next 12 weeks.
Study: NCT02023164
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenhydramine Injection, 50 mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
Study: NCT04860284
Drug: Hydroxychloroquine tablets
Normalized name: hydroxychloroquine Oral Tablet
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine tablets 400mg given orally 12 hourly on day 1 and 200mg 12 hourly on day 2 to 5
Study: NCT02665234
Drug: 1% Tavilermide Ophthalmic Solution
DrugBank: Tavilermide (DB12441)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Tavilermide BID Dosing
Study: NCT03622593
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept 2 mg was administered by intravitreal (IVT) injection into the study eye once every 8 weeks (Q8W).
Study: NCT03622593
Drug: Faricimab
Normalized name: Faricimab
DrugBank: Faricimab (DB15303)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Faricimab 6 mg was administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or according to a personalized treatment interval (PTI) in arm B.
Study: NCT01691872
Drug: Retigabine
Normalized name: retigabine
DrugBank: Ezogabine (DB04953)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Retigabine
Study: NCT03017248
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketamine
Study: NCT03017248
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine
Study: NCT02145923
Drug: Bone marrow derived allogeneic MMSCs infusion
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02678741
Drug: TLPLDC Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor Lysate, Particle Loaded, Dendritic Cell Vaccine
Study: NCT01725152
Drug: Ganaxolone
Normalized name: ganaxolone
DrugBank: Ganaxolone (DB05087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral suspension, given in 3 divided doses
Study: NCT03301766
Drug: lidocaine 5% patch
Normalized name: LIDOCAINE 5% PATCH
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: transdermal patch
Study: NCT00083070
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04514237
Drug: BOS172767 enantiomer E1 or E2
Normalized name: edaravone
DrugBank: Edaravone (DB12243)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral tablets
Study: NCT02640846
Drug: Milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corotrope will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.
Study: NCT02640846
Drug: Levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.
Study: NCT01808313
Drug: ambrisentan
Normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ambrisentan 5 mg will be administered to eligible subjects for 12 weeks
Study: NCT01236612
Drug: Chloroquine prophylaxis
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The chloroquine dose used will be 300mg for the first two days, followed by 300mg per week, for 13 weeks.
Study: NCT03176693
Drug: Phenoxybenzamine
Normalized name: Phenoxybenzamine
DrugBank: Phenoxybenzamine (DB00925)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-selective alpha blocker
Study: NCT03176693
Drug: Doxazosin
Normalized name: Doxazosin
DrugBank: Doxazosin (DB00590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selective alpha blocker
Study: NCT00003982
Drug: sabarubicin
Normalized name: Sabarubicin
DrugBank: Sabarubicin (DB12410)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02814968
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03161938
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous
Study: NCT00782418
Drug: Comparator: exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: exenatide in two 5mcg subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 5mcg doses will be administered, followed by HCG or GGI.
Study: NCT00782418
Drug: Comparator: exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: exenatide in two 1.5mcg subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 1.5mcg doses will be administered, followed by HCG or GGI.
Study: NCT04393584
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: d1 Irinotecan 180mg/m² every two weeks
Study: NCT04393584
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: d1-2 5-FU 2450 mg/m² every two weeks
Study: NCT01178853
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin 5 mg once daily
Study: NCT04393584
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: d1 Oxaliplatin 85 mg/m² every two weeks
Study: NCT04393584
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: d1 Docetaxel 50mg/m2 every two weeks
Study: NCT01163162
Drug: Paricalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mcg oral Paricalcitol once per day for 7 days
Study: NCT04137276
Drug: vitamin B1
Normalized name: Vitamin B1
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: thiamine 200 mg/12 hours for 3 days
Study: NCT01178853
Drug: Warfarin 5 mg + Pitavastatin 4mg once daily (QD)
Normalized name: lisinopril
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin 5 mg + Pitavastatin 4mg
Study: NCT04783753
Drug: EDP-514
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive EDP-514 on Days 1 and 14
Study: NCT04783753
Drug: EDP-514
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive EDP-514 on Days 1 and 23
Study: NCT01218932
Drug: A
Normalized name: Ac
DrugBank: Actinium (DB12860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in A group who receive regimen 1 of primaquine (PQ) on the first admission (visit 2) will receive regimen 2 of primaquine and chloroquine combination (PQ and CQ) on second admission (visit 3) after 1 week wash out period and will finish with regimen 3 of Chloroquine (CQ) on the third admission (visit 4) after 8 weeks wash out period.
Study: NCT01218932
Drug: B
Normalized name: Bk
DrugBank: Berkelium (DB12993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in B group who receive regimen 1 of primaquine ( PQ) will receive regimen 2 of chloroquine (CQ) on second admission (visit 3) after 1 week wash out period and regimen 3 of primaquine and chloroquine combination (PQ and CQ)on third admission( visit 4) with 8 week wash out period in between.
Study: NCT00788515
Drug: Volinanserin (M100907)
Normalized name: Volinanserin
DrugBank: Volinanserin (DB16351)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg tablets QD
Study: NCT00788515
Drug: Lormetazepam
Normalized name: lormetazepam
DrugBank: Lormetazepam (DB13872)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg tablets (overencapsulated) QD
Study: NCT00411788
Drug: Rapamycin
Normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral rapamycin 6 mg daily
Study: NCT00411788
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab 4 mg/kg will be administered (intravenous) on day 1, and this will be followed by weekly dose of 2 mg/kg starting day 8.
Study: NCT00878917
Drug: Dorzolamide 2 % eye drops solution
DrugBank: Dorzolamide (DB00869)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 drop into eye(s) three times a day for the duration of each treatment phase
Study: NCT00109187
Drug: Xolair (omalizumab)
Normalized name: omalizumab Injection [Xolair]
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01762293
Drug: Famitinib
Normalized name: Famitinib
DrugBank: Famitinib (DB11741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famitinib 25 mg p.o. qd
Study: NCT04209296
Drug: Ketamine Hydrochloride
Normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine, a N-methyl-D-aspartate (NMDA) receptor antagonist has been used for general anesthesia since the 1970s, however, reports and trials by the end of the twentieth century and onward using subanesthetic doses suggested robust and rapid antidepressant and anti-suicidal effects. Ketamine is available as a 50/50 racemic mixture of enantiomers (S)-ketamine and (R)-ketamine.
Study: NCT00048594
Drug: aprepitant
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04783753
Drug: EDP-514
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive EDP-514 on Days 1 and 8
Study: NCT04783753
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive itraconazole QD for 14 days
Study: NCT04783753
Drug: Carbamazepin
Normalized name: Carbamazepin
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive carbamazepine BID for 23 days
Study: NCT01438749
Drug: diazepam
Normalized name: Diazepam
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose
Study: NCT03535233
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03535233
Drug: Minoxidil 5 % Topical Spray
Normalized name: minoxidil 5 % Topical Spray
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03535233
Drug: clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01076634
Drug: insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.4 U/kg body weight. Injected subcutaneously (under the skin) once daily for 8 days.
Study: NCT02529761
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).
Study: NCT02568839
Drug: docetaxel + trastuzumab sc + pertuzumab
Normalized name: hyaluronidase / pertuzumab / trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: docetaxel 75-100 mg IV + trastuzumab sc 5 ml (600 mg) SC + pertuzumab 840 mg IV starting dose, subsequently 420 mg IV, repeated every 3 weeks, 6 courses
Study: NCT02546674
Drug: Nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A daily dose of 300 mg was given to all participants as two 150 mg capsules BID. The prescription of study drug was not study dependent and followed medical needs of the participant only. The study treatment was administered for 24 months.
Study: NCT04310150
Drug: Collastat
Normalized name: docusate
DrugBank: Docusate (DB11089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hemostatic agent that combine porcine-derived collagen thrombin
Study: NCT02555761
Drug: Alcaftadine Ophthalmic Solution 0.25%
DrugBank: Alcaftadine (DB06766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcaftadine Ophthalmic Solution 0.25% (Lastacaft®) as prescribed as standard of care in clinical practice.
Study: NCT02568839
Drug: trastuzumab emtansin
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: trastuzumab emtansine 3.6 mg/kg IV, repeated every 3 weeks, 6 courses
Study: NCT00005986
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005986
Drug: filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00005986
Drug: recombinant interferon alfa
Normalized name: INTERFERON ALFA-2A,RECOMBINANT
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00543569
Drug: Alefacept
Normalized name: Alefacept
DrugBank: Alefacept (DB00092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as a 7.5 mg intravenous bolus on day 0 (intraoperatively, prior to kidney revascularization) and Day 3; subsequently administered subcutaneously either weekly or every 2 weeks.
Study: NCT00543569
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The initial dose of tacrolimus was administered orally within 48 hours post-transplant. Subsequent doses were to be adjusted to achieve target whole blood trough concentrations.
Study: NCT00543569
Drug: basiliximab
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered as a 20 mg bolus injection within 2 hours prior to transplantation and a 20 mg bolus injection on Day 3.
Study: NCT00543569
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered at 750 mg twice per day orally or intravenously for patients enrolled under Amendment 6 or earlier and at 1000 mg twice per day orally or intravenously for patients enrolled under Amendment 7. The dose of MMF could be adjusted based on clinical symptoms.
Study: NCT02641236
Drug: Vancomycin-polymyxin B
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00905307
Drug: OPC-34712
Normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, once daily
Study: NCT00905307
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral, once daily
Study: NCT00446446
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab was administered over a 1 hour intraveneous (IV) infusion at a dose of 9 mg/kg every 21 days.
Study: NCT02304536
Drug: FSH
Normalized name: FSH
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 70 women will receive urinary purified FSH (Fostimon® IBSA, Switzerland) 75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days. The cycle will be cancelled if no follicles exceed 9mm 4 weeks after starting FSH. This was combined with oral metformin (Cidophage® CID, Egypt) 500 mg three times per day
Study: NCT02671695
Drug: Spirulina
Normalized name: Spirulina
DrugBank: Spirulina platensis (DB14744)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina capsules (500 mg) in a dose of 250 mg/kg/day orally for 3 months
Study: NCT02671695
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine in a dose of 5 mg/day orally for 3 months